Who can take part?
Patients with Castrate Resistant Metastatic prostrate cancer.
What is involved for you?
Your doctor will prescribe a hormone tablet for your prostate cancer. There are two similar but slightly different tablets available – abiraterone (Zytiga®), which is taken as two tablets daily (500mg each) and enzalutamide (Xtandi®), which is taken as four capsules daily (40mg each). You will also be asked to continue your regular hormonal injections (androgen deprivation therapy (ADT)) as per your standard treatment. Half of all participants in this trial will take their hormone tablet in the standard fashion. Half will take breaks in treatment when a blood test shows that the tablets have worked to control the cancer. You will see the doctor and study nurse every four weeks for a physical exam and blood test. This blood test will monitor how the treatment is working with a PSA blood test.